Tauklarify (florquinitau F 18 injection) is an FDA-approved tracer for tau PET imaging, a scan that makes tau tangles visible during Alzheimer evaluation. For adults with new memory symptoms in 2026, the headline means a new evaluation tool exists, not a reason to seek a scan. Headlines overread when they present the image as a diagnosis by itself.
The Enigma Biomedical USA and Lantheus announcement describes the use as adults with cognitive impairment being evaluated for Alzheimer disease, including early-stage patients. It is not screening for people without symptoms. A clinical exam comes first.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the scan adds to evaluation
- Who the test fits — and who it does not
- Why positive and negative scans have limits
- What to do about new memory symptoms
What the scan adds to evaluation
Tau tangles are clumps of abnormal tau protein linked to Alzheimer disease. PET is a scan that detects a tracer, an injected drug that attaches to a target. Reuters reported that Tauklarify is injected before scanning to show abnormal tau deposits and help assess Alzheimer disease during clinical evaluation, described in the Reuters account of the approval.
The image does not replace memory testing, history, blood work, or other brain checks. It adds one biological signal to that workup. A doctor reads it alongside symptoms and other results.
Who the test fits — and who it does not
The fit is adults who already have cognitive impairment and are being evaluated for Alzheimer disease. That includes people at an early stage with new problems in memory, thinking, or daily function. People without symptoms seeking routine brain screening are outside this use.
NeurologyLive reported that approval relied on two large independent studies, with 68%-88% positive agreement and 93%-99% negative agreement across five blinded readers. The studies also showed strong agreement between readers and safety data from 1,734 subjects, detailed in the FDA approval report. Agreement here means how often scan reads matched the reference standard.
Why positive and negative scans have limits
A clear scan is reassuring but not final. Practical Neurology reported that a negative Tauklarify scan does not exclude tau pathology, while a positive scan does not by itself confirm histopathologic tau tangles. Performance may be lower in earlier pathologic stages, noted in the Practical Neurology summary of limits.
The Lantheus prescribing information also limits use to Alzheimer evaluation. Safety and effectiveness have not been established for non-Alzheimer tauopathies. The scan therefore cannot distinguish other tau diseases.
What to do about new memory symptoms
Start with clinical care, not imaging. Healio reported 2025 guidance from the Alzheimer's Association and SNMMI that amyloid and tau PET should be ordered only when results will directly affect care, such as treatment eligibility, explained in the appropriate-use guidance.
That rule prevents costly scans that change nothing. Bring a symptom list, drug list, and a family member who sees daily function. Ask for the plan in writing before any referral.
- Get a clinical cognitive assessment and basic medical workup first
- Ask what other causes were excluded, such as drugs, sleep, mood, or thyroid issues
- Ask how a tau PET result would change diagnosis, treatment, or trial eligibility
- Seek the scan only if the clinician says the answer would change management
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
